التفاصيل البيبلوغرافية
| العنوان: |
Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
| المؤلفون: |
Francisco Bosques-Padilla, MD, Rafael Trejo-Estrada, MD, Octaivio Campollo-Rivas, MD, Carlos Cortez-HernÁndez, MD, Margarita Dehesa-Violante, MD, Héctor Maldonado-Garza, MD, Raúl Pérez-Gómez, MD, Armando Cabrera-Valdespino, MD |
| المصدر: |
Annals of Hepatology, Vol 2, Iss 3, Pp 135-139 (2003) |
| بيانات النشر: |
Elsevier, 2003. |
| سنة النشر: |
2003 |
| المجموعة: |
LCC:Specialties of internal medicine |
| مصطلحات موضوعية: |
Chronic hepatitis C, Peginterferon alfa-2a efficacy, Early prediction response, Treatment security., Specialties of internal medicine, RC581-951 |
| الوصف: |
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus rib-avirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Thirty-two patients were randomly assigned to treatment, and received at least one dose of medication consisting of 180 μ of peginterferon alfa-2a once weekly plus daily ribavirin (1,000 or 1,200 mg, depending on body weight) (n = 14), weekly peginterferon alfa-2a plus daily placebo (n = 6), or three million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks (n = 12). More patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than patients who received interferon alfa-2b plus ribavirin (7/14 vs. 4/12) or peginterferon alfa-2a plus placebo (0/6). The overall safety profiles of the three treatment regimens were similar. In conclusion, for patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained viral reduction compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1665-2681 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S1665268119321398; https://doaj.org/toc/1665-2681 |
| DOI: |
10.1016/S1665-2681(19)32139-8 |
| URL الوصول: |
https://doaj.org/article/7b8ef9abd4a6429394e1c4c88e5ab32f |
| رقم الانضمام: |
edsdoj.7b8ef9abd4a6429394e1c4c88e5ab32f |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder